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Circulating tumour cell (CTC) enumeration and profiling has been established as a valuable clinical tool 
in many solid malignancies. A key challenge in CTC research is the limited number of cells available for 
study. Ex vivo CTC culture permits expansion of these rare cell populations for detailed characterisation, 
functional assays including drug sensitivity testing, and investigation of the pathobiology of 
metastases. We report for the first time the establishment and characterisation of two continuous 
CTC lines from patients with gastroesophageal cancer. The two cell lines (designated UWG01CTC and 
UWG02CTC) demonstrated rapid tumorigenic growth in immunodeficient mice and exhibit distinct 
genotypic and phenotypic profiles which are consistent with the tumours of origin. UWG02CTC exhibits 
an epcAM+, cytokeratin+, CD44+ phenotype, while UWG01CTC, which was derived from a patient 
with metastatic neuroendocrine cancer, displays an EpCAM−, weak cytokeratin phenotype, with 
strong expression of neuroendocrine markers. Further, the two cell lines show distinct differences in 
drug and radiation sensitivity which match differential cancer-associated gene expression pathways. 
This is strong evidence implicating EpCAM negative CTCs in metastasis. These novel, well characterised, 
long-term ctc cell lines from gastroesophageal cancer will facilitate ongoing research into metastasis 
and the discovery of therapeutic targets.
Gastroesophageal cancers are among the most common and lethal cancers worldwide1. Most patients present 
with locally advanced or metastatic disease, or develop recurrent disease following curative surgery2. While many 
systemic treatment options are available, the prognosis of advanced gastroesophageal cancer remains poor, with 
median survival of less than 1 year3. Greater than 90% of gastric and gastroesophageal junction cancers are ade-
nocarcinomas, with gastrointestinal stroma tumours (GIST), lymphomas, and neuroendocrine tumours found 
in a small minority of cases4.
Most patients with gastroesophageal cancer will require systemic treatment at some point in their treatment3. 
There is an increasing recognition of the limitations of using primary tumour features to guide systemic cancer 
treatment, due to tumour heterogeneity and the frequent disparity observed between primary and metastatic 
sites5. Metastatic biopsies are rarely undertaken however, due to both inaccessibility of metastatic sites and pro-
cedure morbidity. Circulating tumour cells (CTCs) are the likely intermediates of metastasis dissemination of 
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cancer, and as such, can be expected to include the subpopulations which are responsible for disease progression6. 
While CTC enumeration has an established prognostic role, the true promise of CTCs is to provide a ‘real time’ 
view of the cancer using only peripheral blood samples, avoiding the need of repeat invasive biopsies7.
Moreover, while most cancer deaths are due to the haematological spread of metastases, research into the 
mechanism of metastasis initiation, formation, and propagation has been hampered by limited access to cancer 
cells within the various stages of the metastatic cascade. CTCs additionally provide a unique window into the 
biology of cancer as it spreads through the blood stream. The rarity of CTCs compared to normal blood cells has 
provided significant technical challenges in developing isolation methods which are sufficiently sensitive and 
specific8.
CTC culture provides an expanded cell population for expression analysis, functional assays, and drug sensi-
tivity testing9,10, and long-term primary CTC cultures provide an ideal laboratory tool for the investigation of the 
biology of metastasis formation11. However, establishment of long-term primary CTC cell cultures has proved 
to be challenging. To date, despite intensive efforts, only several long-term CTCs cultures have been reported 
worldwide, including in colorectal12, breast13, and prostate14 cancer, all established with modest success rates, 
with 1–16% of blood samples producing stable cultures. To improve culture rates, initial expansion of the CTC 
population using xenotransplantation into immunodeficient mice prior to in vitro culture has been trialled1,15.
In this current work we describe establishment of two novel and distinct CTC cell lines derived from patients 
with metastatic gastroesophageal cancer.
Results
establishment and validation of long-term in vitro ctc cultures from patients with metastatic 
gastroesophageal cancer. A total of 41 blood samples were processed for CTC enumeration, with 23 sam-
ples processed for culture using the optimised protocol (15 ml blood sample with negative selection using the 
CTC Enrichment Cocktail). CTCs were detected in 38/40 samples (93%) by EpCAM (epithelial cell adhesion 
molecule) based capture using the IsoFlux system (one specimen clotted and was not processed for CTC enumer-
ation), with ≥10 CTCs found in 22 (54%) of the samples. Numbers of CTCs detected ranged from 0–150, with the 
mean number of CTCs 27.3 (summarised in Supplementary Table 1).
Long-term continuous CTC lines were established from two male patients using the optimised protocol 
(Table 1) and in both cases viable, relatively pure cultures were seen within 3 weeks, expanded rapidly, and have 
been maintained continuously for over 12 months to date. The first CTC line was established from patient 20 (cell 
line UWG01CTC), who had a low CTC count of 3 by EpCAM based capture despite widespread nodal and bone 
metastases. Patient 20 had a distal oesophageal/gastroesophageal junction carcinoma diagnosed on endoscopy in 
October 2015. He received concurrent chemoradiotherapy to the primary tumour and locoregional nodal disease 
as planned neoadjuvant treatment. Despite an excellent local response to chemoradiotherapy, he rapidly devel-
oped widespread metastatic disease including a dural metastasis causing spinal cord compression. At the time 
of CTC sampling he underwent resection of this metastasis, with histopathology demonstrating high grade neu-
roendocrine carcinoma, a rare and highly lethal subtype of cancer occurring in <1% of patients with gastrointes-
tinal cancers16. Unfortunately, patient 20 progressed rapidly prior to receiving further treatment and passed away.
The second long-term culture was established from patient 41 (cell line UWG02CTC) who had a high CTC 
count of 109. This patient presented with diffuse bone and peritoneal metastasis. Endoscopy demonstrated a large 
ulcerated gastric mass confirmed on biopsy to be a gastric adenocarcinoma. A matched culture was established 
simultaneously from the ascitic fluid sample from the same patient (UWG02ASC). Patient 41 also progressed 
rapidly prior to receiving any anti-neoplastic treatments and passed away.
The CTC lines display discrete in vitro growth characteristics. UWG01CTC is adherent and requires trypsin-
isation for passaging, although a loose adherent spheroid phenotype is inducible in a hypoxic environment and 
serum free media (Fig. 1A). In contrast, both UWG02CTC (Fig. 2A) and UWG02ASC (data not shown) grow in 
long mucinous, loosely aggregated and weakly adherent strands which requires only gentle mechanical dissocia-
tion for passaging. All established cell lines have been adapted to grow in a variety of conditions, including serum 
free media supplemented with various growth factors, normoxic atmosphere, or ultra-low attachment (ULA) or 
standard culture vessels, and remain viable after freezing and thawing at various passages.
When injected subcutaneously into flanks of immunodeficient mice, both CTC lines rapidly formed 
tumours in all mice (n = 3 for each cell line), reaching tumour size endpoints (>10 × 10 mm) within 4 weeks 
for UWG01CTC (Fig. 1B) and 3 weeks for UWG02CTC (Fig. 2B). UWG02ASC also rapidly formed tumours 
(Fig. 2B). IHC on excised tumours confirmed identical expression of human cytokeratins and cell surface protein 
markers to the original patient tumour and corresponding cell line (Figs. 1D and 2D). Cell cultures were also 
successfully derived from mouse xenografts (denoted UWG01CTC-M, UWG02CTC-M and UWG02ASC-M to 
indicate passage through mice).
Patient Number/
Cell line ID Primary Tumour
Sites of metastatic 
disease at blood draw
Treatment prior to blood 
sampling
CTC count (IsoFlux, 
7.5 ml blood)
Key protein expression 
of cell line
20/UWG01CTC
Distal oesophageal high 
grade neuroendocrine 
carcinoma
Widespread bone, 
nodal, and hepatic
Chemoradiotherapy with 
carboplatin and paclitaxel 
to primary tumour and 
regional nodal disease
3
Synaptophysin+ CGA+ 
CD56+ EpCAM−
Cytokeratin weak/low
41/UWG02CTC Gastric adenocarcinoma Bone and peritoneal Nil 109 EpCAM+ Cytokeratin+ CD44+
Table 1. Characteristics of the source patients of long-term CTC cell lines.
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Cell line authentication. Detailed DNA analyses were limited by poor DNA quality from both source 
patients’ formalin fixed paraffin embedded (FFPE) samples. However, by STR analysis, 24/28 (85.8%) alleles 
of UWG02ASC and UWG02CTC were identical to those of the primary tumour from patient 41, confirming 
the source of the cell lines (see Supplementary Table 2). Despite multiple attempts, there was inadequate DNA 
extracted from patient 20 for any analyses including STR. However, the STR profile of UWG01CTC did not 
match any known cell lines in the American Type Culture Collection (ATCC) or Deutsche Sammlung von 
Mikroorganismen und Zellkulturen (DSMZ) databases, confirming that UWG01CTC is a novel high grade neu-
roendocrine CTC line.
Further, UWG01CTC and UWG02CTC were analysed by targeted next generation sequencing and exhibited 
characteristic cancer gene amplifications or mutations for high grade neuroendocrine17,18 and gastric adenocar-
cinomas19, respectively (Supplementary Table 3).
CTC derived cell lines recapitulate the pathological characteristics of source patients. Patient 
20 primary tumour, UWG01CTC and xenograft demonstrated high grade poorly differentiated appearances by 
Hematoxylin and Eosin (H + E) stain (Fig. 1D) with a high Ki67 (>80%) (Fig. 1C). UWG01CTC displayed only 
weak patchy cytokeratin staining (Fig. 1D), but as expected expressed high levels of the neuroendocrine markers 
synaptophysin, CD56, and chromogranin A (Fig. 1C,D) as is typical of high grade gastroesophageal neuroendo-
crine tumours. Protein expression of synaptophysin was constant from cell line to mouse xenograft and subse-
quent cell culture propagated from the xenograft (UWG01CTC-M, Fig. 1D). UWG01CTC and its derivatives had 
an otherwise negative IHC profile, with no staining for epithelial or stem cell markers (Figs. 1C and 3A).
The primary tumour of patient 41 and UWG02CTC both demonstrated high grade appearances by H + E 
stain (Fig. 2D) with a high Ki67 (>80%) (Fig. 3A). As expected in adenocarcinoma, both the tumour and cell line 
strongly expressed cytokeratins (pancytokeratin; Fig. 3A), in particular CK-20 (Fig. 2D). UWG02ASC displayed 
Figure 1. Characteristics of patient 20 tumour and UWG01CTC cell line. (A) Representative images of 
late passage (passage 40) UWG01CTC under hypoxic conditions in standard culture vessels with 10% 
FCS containing media (top image) or serum free media where they form loose spheroids (bottom image). 
Scale bar 50 µm. (B) UWG01CTC rapidly formed tumours in immunocompromised mice (n = 3), with all 
tumour endpoints reached within 3 weeks. (C) IHC analysis of UWG01CTC showing strong expression of 
neuroendocrine markers (CD56 and CGA), high Ki67 expression, but no expression of CSC markers (CD44, 
CD133, ALDH1). (D) IHC analyses of patient 20 tumour, patient derived cell line, mouse xenograft, and cell 
line derived from mouse xenograft (UWG01CTC-M) showing stable strong expression of the neuroendocrine 
marker synaptophysin, with consistent patchy cytokeratin positivity. Scale bar 100 µm.
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an almost identical phenotype to UWG02 CTC (Fig. 2D, Supplementary Figure 1) except for the gastric cancer 
stem cell marker CD44, which was strongly positive in UWG02CTC but negative in UWG02ASC (Fig. 2C).
Differing media (10% FCS or serum free media) did not change the phenotype of any cell line as detected by 
IHC (data not shown). Neither CTC cell line expressed mesenchymal markers (vimentin or N-cadherin) or urok-
inase plasminogen activator receptor (uPAR), a key receptor for the initiation of proteolytic cascades20 by IHC 
(Fig. 3A). UWG02CTC strongly expressed EpCAM and E-cadherin proteins (Fig. 3A). No cell line showed any 
CD45 expression at any stage confirming these cultures did not derive from lymphocytes (Fig. 3A).
Expression of key IHC markers was maintained in each cell line in monolayer culture through to xenograft, and 
return to in vitro culture. These include neuroendocrine markers in UWG01CTC such as chromogranin A, CD56, 
and synaptophysin (Fig. 1C,D), and cytokeratin markers seen in adenocarcinomas in UWG02CTC (Supplementary 
Figure 1). No significant impact of varying in vitro culture conditions such as O2 levels, passage number, growth as 
a spheroid, and post xenograft culture compared to in vivo (xenograft) growth was observed on NanoString gene 
expression profiles using unsupervised hierarchical clustering, though monolayer (2D) cultures grouped together 
and away from spheroids (3D) and xenografts, which grouped together (Supplementary Figures 2 and 3A). While all 
patient 41 derived cultures and xenografts grouped away from the source tumour, global significance scores indicated 
that most gene sets (of key cancer pathways) genes exhibited little differential expression between UWG02CTC/ASC 
xenografts and the source tumour (Supplementary Figure 3B). Differential expression became more extensive as the 
culture models went from 3D to 2D compared to the source tumour (Supplementary Figure 3B). The CTC and ASC 
derived cultures and xenografts grouped closely together in all unsupervised clustering analyses with no significant 
gene expression differences observed confirming their common tumour of origin (Supplementary Figure 3A).
Thus the two established CTC cell lines not only demonstrate markedly different phenotypes that faithfully 
recapitulate those of their source tumours (Figs. 1–3), but also maintenance of their phenotype under the various 
in vitro and especially in vivo conditions tested, indicating their phenotypic stability.
CTC cell lines have distinct gene expression profiles. The IHC and STR findings, showing two highly 
distinct CTC lines, were further explored by NanoString analyses. As expected the sample cohorts derived from 
patient 20 versus patient 41 grouped together by unsupervised hierarchical clustering (Supplementary Figure 4A). 
Figure 2. Characteristics of patient 41 tumour, UWG02CTC and UWG02ASC cell lines. (A) Representative 
images of the loose aggregates formed by UWG02CTC. Scale bar 50 µm. (B) Both UWG02CTC (n = 3, open 
squares) and UWG02ASC (n = 2, solid dots) rapidly formed tumours in immunocompromised mice, with all 
mice reaching tumour endpoints within 4 weeks. (C) Expression of cancer stem cell markers in UWG02CTC 
and UWG02ASC. Scale bar 100 µm. (D) IHC analyses of primary tumour, UWG02CTC and UWG02ASC. Both 
cell lines showed strong CK-20 and weak CK-7 staining, with an identical expression profile in tumours formed 
in the mouse xenograft. Scale bar 100 µm.
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Figure 3. Comparison of UWG02CTC versus UWG01CTC. (A) Immunohistochemical analysis of the 
expression of key proteins. The distinct phenotypes of the two CTC cell lines are highlighted in this figure; 
UWG02CTC expresses epithelial markers (EpCAM and E-Cadherin) as well as strong cytokeratin staining. 
In contrast UWG01CTC has no epithelial staining and weak/patchy cytokeratin staining. Both cell lines show 
high Ki67 expression supporting a high proliferation rate. No CD45 staining was seen in any of the cell lines. 
Scale bar 100 µm. (B) Heat-map (unsupervised hierarchical clustering) of selected gene expression profiling of 
CTC cultures (UWG01CTC versus UWG02CTC) with matching mouse xenografts. Count data has undergone 
z-score transformation to give equal mean and variance across the samples. Orange indicates a higher score, 
blue indicates a lower score.
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The majority of genes included in this NanoString gene panel were significantly differentially expressed between 
Patient 20 derived CTC cultures and xenografts compared to Patient 41 derived CTC cultures and xenografts 
(Supplementary Figure 4B). We then compared the expression of a subset of genes known to distinguish neu-
roendocrine from adenocarcinoma tumours using the CTC derived cultures and xenografts only. As expected 
UWG01CTC had higher expression of genes for neuroendocrine markers including CNTFR, PAX-5 and NGFR21–23  
(Fig. 3B). UWG02CTC had higher expression of CDH1 (encoding E-cadherin) relative to UWG01CTC (−log2 
9.4 fold). Interestingly, UWG02CTC when compared to UWG01CTC, had a higher expression of genes known to 
be involved in Helicobater pylori mediated carcinogenesis such as AKT24, ETS225 and MYC26 (Fig. 3B), supporting 
endoscopic finding that patient 41’s tumour was likely related to H. pylori gastritis. There was also upregulation 
of genes encoding for the gastric cancer stem cell markers CD44, ALDH1 and CD133, as well as key stem cell 
pathways such as NOTCH and WNT., These included the notch ligand delta-like ligands (DLL-1 and DLL-4) and 
PLA2GA, an important regular of metastases in gastric cancer and expressed with constitutively active Wnt27–29. 
UWG02CTC also showed higher expression than UWG01CTC of targetable pathways including EGFR, FGFR2, 
HER-2 (ERBB2), and MET, as well as key genes in the JAK/STAT pathway, genes which overexpression are fre-
quently reported in gastric adenocarcinomas but not gastrointestinal neuroendocrine cancers16,30,31.
UWG01CTC showed a higher expression of DLL-3, which is known to be expressed on most high grade neu-
roendocrine cancers, particularly small cell lung cancer. Compared to UWG02CTC, UWG01CTC also showed a 
lower expression of key DNA repair kinases, including ATM and ATR. We did not observe other reported molec-
ular features of high grade neuroendocrine cancers such as BCL-2 overexpression or Rb inactivation.
We did not find overexpression of CSC or epithelial to mesenchymal transition (EMT) genes in UWG02CTC 
compared to UWG02ASC and overall these two Patient 41 lines demonstrated very similar gene expression 
profiles.
The CTC lines display differential drug and radiosensitivity profiles. The in vitro sensitivity 
of both CTC and UWG02ASC cell lines to commonly used DNA-damaging chemotherapeutics with varying 
mechanisms of action was evaluated. UWG01CTC and UWG02CTC varied in their sensitivities to these drugs 
as demonstrated by the dose response curves shown in Fig. 4A,B. UWG01CTC was significantly less sensitive 
than UWG02CTC to all drugs including carboplatin and paclitaxel which patient 20 received prior to sampling 
for CTC culture (Table 2). UWG02CTC was 30–40× more sensitive to both doxorubicin and etoposide than 
UWG01CTC (Table 2). Indeed, UWG02CTC IC50 value for etoposide at 0.036 µM is ~3-fold lower than the min-
imum value reported for other gastroesophageal cancer cell lines (0.136 µM)32, suggesting that patient 41 may 
have benefited from treatment with this drug even though etoposide is more commonly used for neuroendo-
crine tumours. The IC50 values for the other compounds otherwise fall within the ranges reported for other can-
cer cell lines32. Expectedly, UWG02CTC and UWG02ASC cell lines were very similar in their drug sensitivities 
(Supplementary Table 4).
The effect of combination drug treatment of the CTC cell lines was also explored. The Fa-CI plot (Fig. 5A) 
shows slight synergism for UWG01CTC at all concentrations of carboplatin and etoposide as all the data points 
fell below CI = 1 (average CI value = 0.765). At high Fa (i.e. >90% of cells killed) however, synergism was strong 
(CI = 0.485) (Fig. 5A, Supplementary Table 5A). Patient 20 may have benefited from treatment with this com-
bination of drugs with dose reduction, as the calculated dose reduction index (DRI) for carboplatin and etopo-
side to achieve this synergistic effect was 5.0 and 3.5, respectively (Supplementary Table 5A). Oxaliplatin and 
5-fluorouracil are routinely used in combination in the treatment of metastatic gastric adenocarcinomas how-
ever, when used against UWG02CTC, no synergism was evident with additive effects at middle range concentra-
tions and a slight antagonism was observed for the lowest and highest concentrations of drug combination used 
(Fig. 5B).
Low dose carboplatin pre-treatment enhances UWG01CTC radiosensitivity. The sensitivity of 
UWG01CTC line to radiotherapy with and without carboplatin sensitisation was investigated using the clono-
genic survival assay. This cell line was radiosensitive with the mean surviving fraction after 1 Gy and 2 Gy being 
0.67 and 0.18, respectively. The addition of low dose carboplatin (1 μM; 40-fold lower dose than IC50) signifi-
cantly enhanced the radiosensitivity of cells resulting in decreased mean surviving fractions compared with cells 
exposed to radiation alone, especially after 1 Gy (Fig. 4C).
Unfortunately, UWG02CTC was unsuitable for this assay as it did not form the requisite colonies. Thus, the 
radiosensitivity of the CTC lines was also compared by flow cytometric analysis of cell cycle distribution 48 h 
post 2 Gy irradiation (Fig. 4D and Supplementary Figure 5). The fraction of UWG02CTC cells in all phases was 
substantially reduced after irradiation compared to control cells (0 Gy) with the majority appearing in sub G0/G1 
indicating that the majority of cells underwent cell death after radiation treatment. In contrast, irradiation led to 
an increased fraction of UWG01CTC cells in G2/M indicating cell-cycle arrest with little evidence of cell death.
Discussion
We report the establishment and characterisation of two novel long-term (>1 year) gastroesophageal cancer cell 
lines derived from CTCs. These two cell lines are genotypically and phenotypically distinct, reflective of differing 
tumour biology in the donor patients. Similar to other reported CTC lines, UWG02CTC displayed an epithelial 
phenotype, with strong expression of EpCAM and pan-cytokeratin. In contrast, UWG01CTC, isolated from a 
patient with neuroendocrine tumour, showed variable and weak cytokeratin (Cam5.2) immunostaining, with 
strong expression of neuroendocrine markers (CD56+, synaptophysin+, chromogranin A+). UWG01CTC had 
no detectable EpCAM, mesenchymal (NCAD, Vimentin), or cancer stem cell marker (CD44, CD133, ALDH1). 
This phenotype makes UWG01CTC a unique EpCAM negative CTC cell line.
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Both CTC derived cell lines recapitulated the phenotype of the source patient’s tumour, highlighting that 
CTCs are a representative tumour source. The RNA expression profiling confirmed these data, with each cell line’s 
expression clustered with the source patient’s tumour and the corresponding mouse xenograft. Both CTC derived 
cell lines demonstrated rapid in vitro and in vivo growth with a high grade histological appearance supportive 
of a stem cell (CSC) phenotype. It was interesting to detect differences in CD44, ALDH1 protein and STAT3 
gene expression between the UWG02CTC and UWG02ASC, which probably reflects the different pathways of 
tumour cell dissemination. Of note, higher expression of CSC markers and key stem pathways was also found on 
UWG02CTC versus UWG01CTC, despite ALDH1, CD44, and CD133 reported as CSC markers in both adeno-
carcinomas and high grade neuroendocrine tumours33,34.
The preserved overall RNA expression profile and IHC staining pattern seen in tumours excised from the 
mice, and the cell cultures (UWG02CTC-M, UWG01CTC-M) derived from these tumours, highlight that these 
procedures, at least in short term cultures, do not grossly alter the original tumour characteristics, making CTC 
Figure 4. Drug responsiveness of CTC cell lines. Representative dose response curves for cytotoxic agents 
against (A) UWG01CTC and (B) UWG02CTC. All analyses were performed in hypoxic conditions. Cell 
viability of treated cells was normalised against vehicle controls, and presented as mean ± SEM (n = 3). 50% 
viability for IC50 is indicated by the grey dotted line. (C) Cell survival of UWG01CTC determined by clonogenic 
assay. Cells were irradiated with or without carboplatin (1 μM). Surviving fractions of irradiated cells only (no 
drug) and drug only were normalized to unirradiated non drug treated control. Each data point represents the 
means ± SEM of at least two independent experiments. (D) Comparison of cell cycle distribution for each cell 
line following radiotherapy. Each cell line has been normalised to the matched untreated control.
Drugs
UWG01CTC UWG02CTC
IC50 (µM)b
Carboplatin 40.80 ± 2.94 (n = 6) 30.50 ± 8.50 (n = 4)
5-Fluorouracil 8.12 ± 3.40 (n = 3)c 1.51 ± 0.24 (n = 5)
Doxorubicin 0.64 ± 0.45 (n = 2) 0.02 ± 0.009 (n = 3)
Etoposide 1.57 ± 0.40 (n = 3)d 0.04 ± 0.021 (n = 3)
Oxaliplatin 0.93 ± 0.26 (n = 2)e 0.18 ± 0.052 (n = 6)
Paclitaxel 0.02 ± 0.01 (n = 5) 0.01 ± 0.003 (n = 3)
Table 2. Drug IC50 values for UWG01CTC and UWG02CTC (from P8 – 40a; all hypoxic conditions). aFrom 
establishment of pure cell line. bMean ± SEM (of n separate experiments as shown). cP = 0.0379 compared to 
UWG02CTC. dP = 0.0209 compared to UWG02CTC. eP = 0.0029 compared to UWG02CTC.
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derived cell lines an excellent model to study tumour biology. Together with the confirmed tumourigenicity of 
the cell lines by the rapid development of tumours (within 4 weeks of inoculation) in all xenografted mice, and 
presence of key mutated and amplified genes that are characteristic of gastric adenocarcinomas or high grade 
neuroendocrine tumours, confirms the establishment of two novel CTC derived immortalised cell lines.
We also undertook cytotoxic and radiotherapy assays of the CTC cell lines based on standard cytotoxic agents 
used for these cancers. We found drug sensitivities were generally similar to those previously reported for gas-
troesophageal cell lines35. All cell lines were very sensitive to radiotherapy, with a synergistic effect of carboplatin 
seen in UWG01CTC. This is consistent with the clinical experience of the radiosensitivity displayed by high 
grade neuroendocrine cancers, driven by low expression of key DNA damage response enzymes, such as ATM 
and ATR36–38. We also explored potential synergistic effects of drug combinations as this may allow clinical dose 
reduction, which in turn reduces toxicity while retaining the therapeutic efficacy.
Multiple other potential therapeutic targets were identified by RNA expression profiling. UWG02CTC had 
high expression of EGFR, FGFR2, ERBB2, and JAK/STAT pathway genes, suggesting potential sensitivity to treat-
ments directed at these validated targets, while UWG01CTC had high expression levels of the DLL3 gene, which 
is proposed as a potentially druggable target39. While these data show that CTC derived cell lines can be used to 
define personalised drug sensitivities for gastric cancer patients, it is important to note the rapid disease pro-
gression and clinical decline of the patients that yielded CTC cultures. The test results in our study would have 
been too late to guide management, and faster protocols are needed to inform personalised therapy in a clinically 
meaningful way. Nevertheless, more comprehensive drug sensitivity testing will be performed on the established 
CTC lines, and may help to define better drug screening libraries for faster future protocols.
Other studies have suggested a high CTC count (>300) is necessary for successful culture12. While we agree 
with this requirement, this issue is complicated by the inherent biases when selecting the isolation method and 
epithelial marker based CTC definition used for enumeration. We employed the standard EpCAM based isolation 
and cytokeratin based CTC identification in the matched blood sample used for CTC enumeration. Due to the 
biological differences discussed above, our successful cultures derived from samples with high (109) and low (3) 
CTC counts, subsequently developing EpCAM positive and negative cell lines, respectively. This finding high-
lights a key issue in the CTC field. While patient 20 has a low EpCAM+ CTC count, which is within the range 
of background cells found to express CTC markers (i.e. false positive CTCs) detected from healthy donor blood 
samples with the IsoFlux system (data not shown), the successful establishment of a CTC cell line argues that this 
patient had a high number of EpCAM− CTCs with the ability to establish metastatic deposits. This hypothesis is 
also supported by the clinical picture. CTC numbers are known to increase with disease burden40, and at the time 
of blood draw patient 20 had high volume and rapidly progressive disease. It is reasonable to suggest this patient 
Figure 5. Combination drug treatment. (A) UWG01CTC and (B) UWG02CTC dose-effect curves and Fa-CI 
plots simulated by the median-effect equation for two drugs shown using CalcuSyn software with actual 
single drug and combination drug data points shown. Representative of at least 2 separate experiments each 
performed in triplicate.
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had a high number of biologically relevant CTCs which were missed using standard CTC isolation techniques. 
The negative selection used for CTC culture (CD45 depletion), rather than the positive selection used for CTC 
enumeration (EpCAM capture) was critical to detect these cells. The optimal isolation method of CTCs contin-
ues to evolve in the face of these issues, and while more emphasis has been given to epithelial to mesenchymal 
transition (EMT) phenotype CTCs in recent years41, the data presented here highlight the persistent challenges 
identifying the optimal markers to isolate CTCs.
Both CTC cell lines displayed a highly aggressive phenotype, with rapid growth, high grade histological 
appearance, and high Ki67 expression. In both cases, this phenotype mirrored the rapid clinical progression seen 
in the corresponding patient. Similar results have been seen in other CTC cell lines12. It is unclear whether this 
finding is indicative that a high proliferation rate is a requirement for successful cultures, or is a result of selection 
pressures for aggressive clones in the culturing process.
The matched culture derived from ascitic fluid (UWG02ASC) simultaneously established from patient 41 as 
UWG02CTC demonstrated an identical phenotype, with the exception of cancer stem cell marker expression. 
UWG02CTC was strongly positive for CD44, a key CSC marker in gastric cancer28, while UWG02ASC was negative 
for CD44. This is consistent with other results showing that CTC cultures exhibit a stem cell phenotype, and further 
supports the notion that CTC cultures develop from the CTC population which are able to establish metastases12,32,42.
In conclusion, we report the first two long-term CTC cell lines developed from patients with metastatic gas-
troesophageal cancer, providing a high fidelity platform for high-throughput gene expression, drug response 
profiling and functional genomics studies. The two CTC cell lines displayed distinct profiles which faithfully 
recapitulate the source patient’s tumour. Our results support the developing role of CTC culture as an essential 
laboratory resource for the understanding of the biology of metastases and importantly undertake personalised 
screening for therapeutic strategies.
Methods
Patient selection and blood collection. Peripheral venous blood samples were collected from patients 
with metastatic gastroesophageal cancer prior to treatment. Patients had histologically confirmed gastric or gas-
troesophageal cancer treated at the Illawarra Cancer Centre, Wollongong Hospital, NSW Australia. Informed 
consent was obtained from each patient prior to enrolment, and the study was approved by South Western Sydney 
Local Health District Human Research Ethics Committee (Project Number 15/072). All experiments were per-
formed in accordance with relevant guidelines and regulations.
Initially 7.5 ml of blood was collected in EDTA tubes. This was increased to 15 ml after seventeen patients were 
enrolled for higher CTC capture to improve culture success rates. Blood samples were transported immediately 
at room temperature for CTC isolation. A separate matched 7.5 ml EDTA blood sample was collected at the same 
blood draw for EpCAM based capture for CTC enumeration using the IsoFlux system (Fluxion Biosciences), 
and processed as per manufacturer instructions43. Enumerated CTCs were defined by the standard EpCAM/
Cytokeratin/DAPI positive and CD45 negative phenotype40.
CTC isolation and cell culture. Blood samples were incubated for 20 min with RosetteSep CTC 
Enrichment Cocktail with anti-CD36 (Stemcell Technologies, Cat. 15167) prior to a density gradient separa-
tion with Leucosep tubes (Stemcell Technologies) to isolate a peripheral blood mononuclear cell (PBMC) layer. 
We initially found excessive lymphocyte contamination prohibiting CTC growth with the RosetteSep Human 
CD45 Depletion Cocktail alone. This improved with changing to the CTC Enrichment Cocktail. The PBMC 
layer was washed twice, then immediately plated into 24-well ultra-low attachment plates (Corning) with serum 
free Advanced DMEM/F12 (ADMEM/F12; Sigma Aldrich) supplemented with epidermal growth factor (EGF; 
Life Technologies), fibroblast growth factor (FGF; Life Technologies) and N2 supplement (Life Technologies), or 
ADMEM/F12 with 10% foetal calf serum (FCS) in hypoxic conditions. Separate CTC cultures were maintained 
in 10% FCS or serum free media. While serum free media is reported to support a cancer stem cell phenotype44, 
in both cell lines successful cultures were established in both media formulations, and we did not find any pheno-
typic differences between media conditions (data not shown). All media was supplemented with antibiotics (see 
Supplementary Table 6 for media formulations).
Patient 41 had marked peritoneal disease and gross ascites from gastric adenocarcinoma. At the same time as 
the blood draw for CTC isolation, 200 ml of ascitic fluid were collected from a peritoneal catheter. This sample 
was transferred immediately to the laboratory, centrifuged to collect a cell pellet, washed twice in ADMEM/F12 
with 1% antibiotic/antimycotic (Sigma Aldrich), and cultured as per conditions listed above. Cultures derived 
from the patient’s CTC and ascites samples were maintained independently under identical conditions. Once 
established as cell lines, for all subsequent routine cell culture and experimental assays, cells were maintained in 
ADMEM/F12 with 10% FCS supplemented with EGF.
Tumourigenicity of cell lines in mouse xenograft models. For confirmation of tumourigenicity, 
1–2 × 106 cells from early passages of each cell line were injected subcutaneously into the flank of NOD scid 
gamma (NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ) mice. Mice were monitored for tumour growth and sacrificed when 
the tumour grew greater than 10 × 10 mm, or the animal demonstrated signs of stress (such as >15% weight 
loss) or evidence of impedance of tumour on movement. Tumours were collected from the sacrificed mice for 
subsequent culture, RNA and DNA extraction, and histological analysis. For culture from xenografts, tumour 
tissues were cut into approximately 1 mm pieces and then incubated with tumour dissociation enzymes (Tumour 
dissociation kit, Miltenyi Biotec) in ADMEM/F12, after which the tumour homogenate was centrifuged, the pellet 
resuspended, and plated in serum-free media and hypoxic conditions as above. All procedures were carried out 
in accordance to the Australian Code for the Care and Use of Animal for Scientific Purposes 8th edition 2013, and 
approved by the University of Wollongong’s Animal Ethics Committee (study AE15/17).
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Immunohistochemical analysis of patient samples, cell lines, and mouse xenografts. 
Expression of key proteins on the cell lines, mouse xenografts, and representative sections from the matching 
patient’s tumour specimen were compared using immunohistochemistry (IHC). For cell lines, cells were col-
lected, centrifuged with supernatant removed, then clotted with plasma and commercially prepared thrombin 
(Fibri-Prest Automate from Stago) to prepare a cell block. All samples were fixed in 10% formalin and paraf-
fin embedded, with 4 µm sections cut for staining. Antigen retrieval and development was performed on the 
fully automated Bond system according to manufacturer’s instructions (See Supplementary Table 7 for antibody 
details), with positive controls included on each slide.
DNA and RNA extraction. Tumour, cell culture and xenograft nucleic acids were extracted using the 
AllPrep DNA/RNA FFPE Kit (80234, Qiagen) or AllPrep DNA/RNA/Protein Mini Kit (80004, Qiagen), respec-
tively, according to the manufacturer’s instructions. All samples were quantified using the NanoDrop (ND1000, 
Thermo Fisher Scientific). DNA/RNA samples had A260/280 ratios between 1.8 and 2.1.
NanoString analysis. Total RNA extracted from fresh-frozen (25 ng) and FFPE (150 ng) specimens were 
run on the NanoString nCounter Sprint system using the 770 gene PanCancer Pathways panel with additional 
cancer stem cell and proteolytic genes as per the manufacturer’s instructions (NanoString Technologies). RNA 
extracted from patient 20 FFPE specimen had low RNA integrity and did not meet the threshold for further anal-
ysis. Results were analysed using the NanoString nSolver 4.0 and Advanced Analysis Module, which normalizes 
gene expression to a set of positive and negative control genes built into the platform45. As recommended, genes 
with expression levels at or below the level of the negative controls were removed from analysis. Differential 
expression of key transcriptomic pathways were compared between cell lines, with fold change and P values cal-
culated using nSolver default settings. With the remaining list of genes, a filter cutoff of fold change ≥ ±2 and P 
value < 0.05 were used to identify the significant gene expression changes46.
Short Tandem Repeat and targeted gene sequencing analysis. STR profiles for the cell lines and 
their matching patient FFPE tumour tissue were verified by the PowerPlex 18D System, using the following 18 
markers (seventeen STR loci and Amelogenin): D3S1358, TH01, D21S11, D18S51, Penta E, D5S818, D13S317, 
D7S820, D16S539, CSF1PO, Penta D, Amelogenin, vWA, D8S1179, TPOX, FGA, D19S433 and D2S1338. As per 
standard practice, cell lines were considered to match if profiles are more than 80% identical to source patient 
sample.
DNA of the cell lines and xenografts were sequenced using the Oncomine Comprehensive v3 Assay on an 
Ion S5 Sequencer (Thermo Fisher Scientific). The assay detects specific hotspots as well as coding sequences 
in particular genes. STR and Oncomine assays were performed by KCCG Sequencing Laboratory & Cancer 
Diagnostics, Garvan Institute of Medical Research, Sydney Australia.
Cytotoxicity assays. Approximately 10,000 cells were seeded per well in triplicate into a 96-well plate 
48–72 h prior to drug treatment. Cells were incubated with serial dilutions of each drug for 72 h with drug vehi-
cle (water, 0.9% saline, or DMSO, depending on drug solubility) and the dilution kept constant across all drug 
concentrations and controls (final concentration of 0.2%). The viability of cells were assayed using CellTitre 96 
Aqueous One Solution Cell Proliferation Assay (Cat # G3581, Promega Corporation, Fitchburg, Wisconsin, USA) 
using a SpectroMax 250 UV plate reader using SoftMax Pro software (Molecular Devices, Sunnyvale, California, 
USA). Cell viability of treated cells was normalized against vehicle controls. This data was analysed using a loga-
rithmic sigmoidal dose–response curve using the variable slope parameter to determine IC50 (GraphPad Prism 
6.0, GraphPad Inc.). Data is presented as a mean ± standard error of the mean (SEM) from ≥2 independent 
experiments.
For combination drug assays cells were seeded as above and then treated with the drug combinations specified. 
The drug concentrations were kept at a constant ratio based on their approximate IC50 values determined as mon-
otherapies and ranged from 0.125×, 0.5×, 1×, 2× and 4× the IC50 of each drug, as optimal for the Chou-Talalay 
median-effect equation47. To determine synergism/antagonism, the combination index (CI) and dose response 
index (DRI) was calculated using CalcuSyn (Biosoft, USA), with Monte-Carlo simulation to assign confidence. 
By the Chou-Talalay method, a CI = 1 represents an additive effect, a CI value > 1 represents antagonism and a 
CI value < 1 represents synergism.
Irradiation procedure and clonogenic survival assay. The sensitivity of the UWG01CTC cells to 
10MV x-ray irradiation with drug pre-treatment was investigated using clonogenic survival as the radiobiologi-
cal endpoint as previously described48. UWG02CTC and UWG02ASC were not suitable for this assay as they 
formed loose and small colonies. Briefly, cells were first acclimated for at least a week in normoxic conditions, 
then plated into 12.5 cm2 tissue culture flasks in regular cell culture media (as above) in order to reach ~60% con-
fluency 3 days later. Cells were then pre-sensitized with 0, 1, 2 and 5 µM carboplatin for 48 h prior to exposure to 1 
or 2 Gy X-Ray radiation delivered in a single fraction at room temperature. Cells were then seeded into triplicate 
tissue-culture petri dishes (100 mm × 20 mm Falcon BD; Pacific Laboratory Products) in 10 mL of ADMEM/
F12 with 10% FCS, pencillin/streptomycin, EGF and L-glutamine, at different cell densities per dish (ranging 
from 1000 to 20000 cells per dish). After approximately 15 doubling times, petri dishes were washed with PBS 
and adherent cell colonies fixed and stained with a 1:3 crystal violet:ethanol solution. Colonies (≥50 cells/col-
ony) were manually counted and presented as Mean Plating Efficiency (MPE; [number of colonies]/[number 
of cells plated]*100) and Surviving Fraction (SF; MPE of treatment group/MPE of control group) as previously 
described49. Unirradiated control samples (with and without drugs) were handled under the same conditions as 
the irradiated samples.
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Cell cycle analysis. Measurements of cell cycle distribution after irradiation were performed essentially as 
previously described50. Cells were irradiated in T12.5 cm3 flasks using a Varian 2100iX linear accelerator. Prior 
to irradiation flasks were completely filled with medium. Flasks were located at midpoint in a 23 cm thick Solid 
Water phantom (Gammex Inc, USA). Flasks were surrounded with Super-Flex bolus (Radiation Products Design 
Inc, USA) to ensure electronic equilibrium. Doses of 1 or 2 Gy were delivered using parallel opposed beam geom-
etry, in a single fraction at room temperature. Briefly, cells (2.0 × 104) were stained with PI master mix (100 μg/
mL RNase A, 40 μg/mL propidium iodide and PBS pH 7.4) for 30 min at 37 °C. DNA content was then measured 
using a Becton Dickinson BD LSR II FACSort flow cytometer (BD Biosciences, USA) and the proportion of cells 
in G0/G1, S and G2/M phases of cell cycle were calculated on the basis of DNA distribution histograms using 
FlowJo software as previous described (V7.1, Tree Star Inc., USA)51.
Statistical analysis. Apart from the NanoString analyses, all the experimental data were expressed as 
means ± SEM and statistically analyzed using GraphPad Prism (version 6.0, USA). For comparisons, two-tailed 
Student’s t test, Fisher’s exact test, one-way analysis of variance test, and Dunnett’s test were performed. P val-
ues < 0.05 were considered statistically significant.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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